Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

Reduction in BP Drives Treatment Preference for Hypertensive Patients

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Registry Data Hint at MACE Benefit with Renal Denervation

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 04, 2021

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

September 25, 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

News Industry News

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

April 09, 2018

News Daily News

Year in Review: Physicians Highlight the Most Important Interventional News of 2014

January 12, 2015

News Daily News

Repaso del Año: Los Médicos Señalan las Noticias Más Importantes en Cardiología Intervencionista de 2014

January 12, 2015

Second Deep Dive into SYMPLICITY HTN-3: Novel Mechanistic Insights from the Trial

Presentation TCT 2014

Second Deep Dive into SYMPLICITY HTN-3: Novel Mechanistic Insights from the Trial

Presenter: David Kandzari

September 14, 2014

Negatory: There are Logical Reasons for Why Renal Artery Denervation Failed in SIMPLICITY HTN-3!

Presentation TCT 2014

Negatory: There are Logical Reasons for Why Renal Artery Denervation Failed in SIMPLICITY HTN-3!

Presenter: Sanjay Kaul, Ajay J. Kirtane, David E. Kandzari

September 13, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

June 24, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Conference News ACC 2014

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Yael L. Maxwell

March 29, 2014

Moderate Treatment Resistant Hypertension: A New Indication for RDN?

Presentation TCT 2013

Moderate Treatment Resistant Hypertension: A New Indication for RDN?

Presenter: David Kandzari

October 27, 2013

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Presentation TCT 2013

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Presenter: David Kandzari

October 27, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.